NCT01533246View on ClinicalTrials.gov

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

linsitinib

Oral Linsitinib 150mg, twice a day, days 1- 28

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

44106

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01533246 - Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter